Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Plos One|April 14, 2017
Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre studyAnita Boyd, Paul Stoodley, David Richards, et al.
ESC Heart Failure|June 18, 2024
Redefining anthracycline-related subclinical cardiotoxicity: 'Absolute' and 'relative' change in longitudinal strainAndrew Terluk, Luke Stefani, Anita Boyd, et al.
Journal of the National Cancer Institute|August 4, 2023
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysisAdel Shahnam, Udit Nindra, Jayesh Desai, et al.
Melanoma Research|May 3, 2016
PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three casesDeepal V Wakade, Giuliana Carlos, Shelley J E Hwang, et al.
Heart, Lung & Circulation|October 23, 2010
The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapyPaul W Stoodley, David A B Richards, Steve R Meikle, et al.
Cancer Research|December 4, 2002
Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cellsRina Hui, Georgina L Finney, Jason S Carroll, et al.
Asia-Pacific Journal of Clinical Oncology|October 6, 2018
Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancerElgene Lim, Jane Beith, Frances Boyle, et al.
Cancer Medicine|November 21, 2022
Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centresLauren J Brown, Ines Pires da Silva, Tania Moujaber, et al.
Immunotherapy|May 16, 2019
Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancerThiru Prasanna, Mal Arasaratnam, Michael Boyer, et al.
Asia-Pacific Journal of Clinical Oncology|October 6, 2018
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigmFrances Boyle, Jane Beith, Katie Burslem, et al.
Pageof 9